VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

BACKGROUND: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, VeriStrat was evaluated a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C, Smit, E F
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3505013/
https://ncbi.nlm.nih.gov/pubmed/23079575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.470
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados